Reply to comment: Screening for active COVID-19 infection prior to biologic therapy in IBD patients: primum non n ŏcēre

We have read with interest the comments to our article [1] written by Festa et al “Screening for active COVID-19 infection prior to biologic therapy in IBD patients: let's not increase our uncertainty without reducing our concerns [2]” recently published on Digestive and Liver Disease. The authors criticized our suggestion to expand the screening commonly recommended prior to the beginning of biologic therapy in Inflammatory Bowel Disease (IBD) patients, to include SARS-CoV-2 RT-PCR and, when available, antibody testing.
Source: Digestive and Liver Disease - Category: Gastroenterology Authors: Source Type: research